

Current management of glaucoma

Current Opinion in Ophthalmology

15, 119-126

DOI: [10.1097/00055735-200404000-00011](https://doi.org/10.1097/00055735-200404000-00011)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Implantable Parylene MEMS for Glaucoma Therapy. , 0, , .		21
2	Topical Dorzolamide 2%/Timolol 0.5% Ophthalmic Solution. <i>Drugs and Aging</i> , 2006, 23, 977-995.	2.7	21
3	Topical Brimonidine 0.2%/Timolol 0.5% Ophthalmic Solution. <i>Drugs and Aging</i> , 2006, 23, 753-761.	2.7	12
4	Bimatoprost. <i>Pharmacoeconomics</i> , 2006, 24, 297-314.	3.3	13
5	Comparison of the efficacy and safety of travoprost with a fixed-combination of dorzolamide and timolol in patients with open-angle glaucoma or ocular hypertension. <i>Current Medical Research and Opinion</i> , 2006, 22, 1799-1805.	1.9	17
6	Effect of temporal clear corneal phacoemulsification on intraocular pressure in eyes with prior Ahmed glaucoma valve insertion. <i>Journal of Cataract and Refractive Surgery</i> , 2006, 32, 1011-1014.	1.5	23
7	Trabeculectomy with Mitomycin C. <i>Ophthalmology</i> , 2006, 113, 930-936.	5.2	172
8	Glaucoma: Current and Developing Concepts for Inflammation, Pathogenesis and Treatment. <i>European Journal of Inflammation</i> , 2006, 4, 129-137.	0.5	18
9	The future of glaucoma clinics. <i>British Journal of Ophthalmology</i> , 2006, 90, 640-645.	3.9	30
10	Daily Cost of Glaucoma Medications in China. <i>Journal of Glaucoma</i> , 2007, 16, 594-597.	1.6	12
11	Long-term Outcomes of Ahmed Glaucoma Valve Implantation in Refractory Glaucomas. <i>American Journal of Ophthalmology</i> , 2007, 144, 893-900.	3.3	142
12	Effect of 2-(6-cyano-1-hexyn-1-yl)adenosine on ocular blood flow in rabbits. <i>Life Sciences</i> , 2007, 80, 1115-1122.	4.3	7
13	Focus on triamcinolone acetonide as an adjunct to glaucoma filtration surgery. <i>Medical Hypotheses</i> , 2007, 68, 401-403.	1.5	8
14	Refill Rates and Budget Impact of Glaucoma Lipid Therapy. <i>Clinical Drug Investigation</i> , 2007, 27, 819-825.	2.2	10
15	GpnmB 150X allele must be present in bone marrow derived cells to mediate DBA/2J glaucoma. <i>BMC Genetics</i> , 2008, 9, 30.	2.7	36
16	Measurement of Intraocular Pressure from the Extra-Ocular Space of the Eye using a MEMS Pressure Sensor. , 2008, , .		0
17	Efficacy of the Ahmed S2 Glaucoma Valve Compared with the Baerveldt 250-mm ² Glaucoma Implant. <i>Ophthalmology</i> , 2008, 115, 1141-1147.	5.2	75
18	Economic evaluation of medication, laser trabeculectomy and filtering surgeries in treating patients with glaucoma in the US. <i>Current Medical Research and Opinion</i> , 2008, 24, 2905-2918.	1.9	56

#	ARTICLE	IF	CITATIONS
19	Nine-year follow-up of trabeculectomy with or without low-dosage mitomycin-c in primary open-angle glaucoma. <i>British Journal of Ophthalmology</i> , 2008, 92, 1666-1670.	3.9	84
20	Primary open angle glaucoma: an overview on medical therapy. <i>Progress in Brain Research</i> , 2008, 173, 181-193.	1.4	8
21	Fixed combination of topical brimonidine 0.2% and timolol 0.5% for glaucoma and uncontrolled intraocular pressure. <i>Clinical Ophthalmology</i> , 2008, 2, 545.	1.8	14
22	Cost comparison of prostaglandin analogues: a Canadian population-based analysis. <i>Journal of Medical Economics</i> , 2008, 11, 299-310.	2.1	1
23	Managing refractory glaucoma with a fixed combination of bimatoprost (0.03%) and timolol (0.5%). <i>Clinical Ophthalmology</i> , 2008, 2, 15.	1.8	6
24	A study of the safety and efficacy of travoprost 0.004%/timolol 0.5% ophthalmic solution compared to latanoprost 0.005% and timolol 0.5% dosed concomitantly in patients with open-angle glaucoma or ocular hypertension. <i>Clinical Ophthalmology</i> , 2008, 2, 313.	1.8	9
25	Trends in Reported Visual Impairment in United States Adults. <i>Ophthalmic Epidemiology</i> , 2009, 16, 42-49.	1.7	12
26	Effect of selected antihypertensives, antidiabetics, statins and diuretics on adjunctive medical treatment of glaucoma: A population based study. <i>Current Medical Research and Opinion</i> , 2009, 25, 1879-1888.	1.9	30
27	Decreased Intraocular Pressure in Mice Following Either Pharmacological or Genetic Inhibition of ROCK. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2009, 25, 187-194.	1.4	37
28	Novel Class of LIM-Kinase 2 Inhibitors for the Treatment of Ocular Hypertension and Associated Glaucoma. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 6515-6518.	6.4	68
29	Bimatoprost/Timolol. <i>Drugs and Aging</i> , 2009, 26, 169-184.	2.7	14
30	“Bleb Window” Pexy for the Management of Symptomatic, Oversized Blebs. <i>Journal of Glaucoma</i> , 2009, 18, 546-551.	1.6	4
31	Primary trabeculectomy with mitomycin C: safety and efficacy at 2 years. <i>Clinical and Experimental Ophthalmology</i> , 2010, 38, 831-838.	2.6	19
32	Efficacy, safety and tolerability of combination therapy with timolol and dorzolamide in glaucoma and ocular hypertension. <i>Drug, Healthcare and Patient Safety</i> , 2010, 2, 73.	2.5	2
33	Cellular Basis for Bimatoprost Effects on Human Conventional Outflow. , 2010, 51, 5176.		36
34	Procedural Treatments: Surgery in End-Stage Glaucoma. , 2010, , 323-330.		2
35	The Development of a RFID Based Mixed Signal ASIC for the Wireless Measurement of Intraocular Pressure. , 2010, , .		8
36	Persistence with Prostaglandin Agonist Use with and without Adjunctive Therapy for Glaucoma Patients. <i>Patient</i> , 2011, 4, 133-141.	2.7	4

#	ARTICLE	IF	CITATIONS
37	Thermal Stability of Bimatoprost, Latanoprost, and Travoprost Under Simulated Daily Use. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2011, 27, 51-59.	1.4	23
38	The Ahmed Versus Baerveldt Study. <i>Ophthalmology</i> , 2011, 118, 2172-2179.	5.2	72
39	The Ahmed Versus Baerveldt Study. <i>Ophthalmology</i> , 2011, 118, 2180-2189.	5.2	317
40	Metabolism of Ophthalmic Timolol: New Aspects of an Old Drug. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2011, 108, 297-303.	2.5	48
41	A poly(μ -caprolactone) device for sustained release of an anti-glaucoma drug. <i>Biomedical Materials (Bristol)</i> , 2011, 6, 025003.	3.3	20
42	In vitro and in vivo evaluation of an intraocular implant for glaucoma treatment. <i>International Journal of Pharmaceutics</i> , 2011, 415, 73-82.	5.2	28
43	Diagnosis and management of ophthalmological features in patients with mucopolysaccharidosis. <i>British Journal of Ophthalmology</i> , 2011, 95, 613-619.	3.9	57
44	Sick sinus syndrome associated with topical timolol maleate instillation. <i>Journal of Pharmacology and Pharmacotherapeutics</i> , 2011, 2, 300.	0.4	10
45	A Survey of Ocular Diseases in an Isolated Rural Haitian Community: A Retrospective Evaluation. <i>Journal of the National Medical Association</i> , 2012, 104, 536-543.	0.8	7
46	The Changing Conceptual Basis of Trabeculectomy: A Review of Past and Current Surgical Techniques. <i>Survey of Ophthalmology</i> , 2012, 57, 1-25.	4.0	110
47	Cysteine-rich protein 61 (CCN1) and connective tissue growth factor (CCN2) at the crosshairs of ocular neovascular and fibrovascular disease therapy. <i>Journal of Cell Communication and Signaling</i> , 2013, 7, 253-263.	3.4	31
48	Adenosine, adenosine receptors and glaucoma: An updated overview. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2013, 1830, 2882-2890.	2.4	68
49	Comparison of adherence and persistence with bimatoprost 0.01% versus bimatoprost 0.03% topical ophthalmic solutions. <i>Current Medical Research and Opinion</i> , 2013, 29, 1201-1209.	1.9	12
50	Adherence, persistence and cost-consequence comparison of bimatoprost topical ocular formulations. <i>Current Medical Research and Opinion</i> , 2013, 29, 1187-1189.	1.9	5
51	Morphological and Hydrodynamic Correlations with Increasing Outflow Facility by Rho-Kinase Inhibitor Y-27632. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2014, 30, 143-153.	1.4	18
52	Newer targets for modulation of intraocular pressure: focus on adenosine receptor signaling pathways. <i>Expert Opinion on Therapeutic Targets</i> , 2014, 18, 527-539.	3.4	18
53	Improvement in Outflow Facility by Two Novel Microinvasive Glaucoma Surgery Implants. , 2014, 55, 1893.		35
54	Perioperative Conjunctival Inflammation and Trabeculectomy Outcome. <i>Ocular Immunology and Inflammation</i> , 2014, 22, 183-188.	1.8	1

#	ARTICLE	IF	CITATIONS
55	<i>In situ</i> gelling ophthalmic drug delivery system: Formulation and evaluation. Journal of Applied Polymer Science, 2014, 131, .	2.6	21
56	Anti-glaucoma potential of Heliotropium indicum Linn in experimentally-induced glaucoma. Eye and Vision (London, England), 2015, 2, 16.	3.0	6
57	Development of an Experimental Drug Eluting Suprachoroidal Microstent as Glaucoma Drainage Device. Translational Vision Science and Technology, 2015, 4, 14.	2.2	21
58	Ultrastructural Changes in Human Trabecular Meshwork Tissue after Laser Trabeculoplasty. Journal of Ophthalmology, 2015, 2015, 1-5.	1.3	19
59	Prevention of Nocturnal Elevation of Intraocular Pressure by Gene Transfer of Dominant-Negative RhoA in Rats. JAMA Ophthalmology, 2015, 133, 182.	2.5	28
60	Modulation of wound healing in glaucoma surgery. Progress in Brain Research, 2015, 221, 319-340.	1.4	15
61	Angiogenesis in glaucoma filtration surgery and neovascular glaucoma: A review. Survey of Ophthalmology, 2015, 60, 524-535.	4.0	48
62	Surgical Outcomes of Superior Versus Inferior Glaucoma Drainage Device Implantation. Journal of Glaucoma, 2015, 24, 32-36.	1.6	14
63	Ability of Bottle Cap Color to Facilitate Accurate Patient-Physician Communication Regarding Medication Identity in Patients with Glaucoma. Ophthalmology, 2015, 122, 2373-2379.	5.2	19
64	Trabeculectomy and Combined Phacoemulsification-Trabeculectomy: Outcomes and Risk Factors for Failure in Primary Angle Closure Glaucoma. Journal of Glaucoma, 2016, 25, 763-769.	1.6	38
65	Prediction of Ocular Drug Distribution from Systemic Blood Circulation. Molecular Pharmaceutics, 2016, 13, 2906-2911.	4.6	39
66	Virus-mediated EpoR76E Therapy Slows Optic Nerve Axonopathy in Experimental Glaucoma. Molecular Therapy, 2016, 24, 230-239.	8.2	37
67	Discovery of Molecular Therapeutics for Glaucoma: Challenges, Successes, and Promising Directions. Journal of Medicinal Chemistry, 2016, 59, 788-809.	6.4	55
68	Pharmacokinetic aspects of retinal drug delivery. Progress in Retinal and Eye Research, 2017, 57, 134-185.	15.5	454
69	Simultaneous Implantation of an Ahmed and Baerveldt Glaucoma Drainage Device for Uncontrolled Intraocular Pressure in Advanced Glaucoma. Journal of Glaucoma, 2017, 26, 101-106.	1.6	4
70	Long-term clinical outcomes of Ahmed valve implantation in patients with refractory glaucoma. PLoS ONE, 2017, 12, e0187533.	2.5	36
71	Discovery and Preclinical Development of Netarsudil, a Novel Ocular Hypotensive Agent for the Treatment of Glaucoma. Journal of Ocular Pharmacology and Therapeutics, 2018, 34, 40-51.	1.4	138
72	Trabeculectomy With Mitomycin-C: Outcomes and Risk Factors for Failure in Primary Angle-closure Glaucoma. Journal of Glaucoma, 2018, 27, 101-107.	1.6	14

#	ARTICLE	IF	CITATIONS
73	Thermo-sensitive gel in glaucoma therapy for enhanced bioavailability: In vitro characterization, in vivo pharmacokinetics and pharmacodynamics study. <i>Life Sciences</i> , 2018, 212, 80-86.	4.3	31
74	Combined Application of Bevacizumab and Mitomycin C or Bevacizumab and 5-Fluorouracil in Experimental Glaucoma Filtration Surgery. <i>Journal of Ophthalmology</i> , 2018, 2018, 1-13.	1.3	6
75	Effects of Early Postoperative Intraocular Pressure after Ahmed Glaucoma Valve Implantation on Long-term Surgical Outcomes. <i>Korean Journal of Ophthalmology: KJO</i> , 2018, 32, 391.	1.1	17
76	Profile of netarsudil ophthalmic solution and its potential in the treatment of open-angle glaucoma: evidence to date. <i>Clinical Ophthalmology</i> , 2018, Volume 12, 1939-1944.	1.8	31
77	Intracranial pressure and glaucoma: Is there a new therapeutic perspective on the horizon?. <i>Medical Hypotheses</i> , 2018, 118, 98-102.	1.5	11
78	Lowered Decorin With Aberrant Extracellular Matrix Remodeling in Aqueous Humor and Tenon's Tissue From Primary Glaucoma Patients. , 2019, 60, 4661.		19
79	In Vitro Study of Combined Application of Bevacizumab and 5-Fluorouracil or Bevacizumab and Mitomycin C to Inhibit Scar Formation in Glaucoma Filtration Surgery. <i>Journal of Ophthalmology</i> , 2019, 2019, 1-10.	1.3	9
80	Steroids and nonsteroidal anti-inflammatory drugs in the postoperative regime after trabeculectomy " which provides the better outcome? A systematic review and meta-analysis. <i>Acta Ophthalmologica</i> , 2019, 97, 146-157.	1.1	19
81	Formulation and investigation of pilocarpine hydrochloride niosomal gels for the treatment of glaucoma: intraocular pressure measurement in white albino rabbits. <i>Drug Delivery</i> , 2020, 27, 888-899.	5.7	29
82	Potential Therapeutic Benefit of NAD+ Supplementation for Glaucoma and Age-Related Macular Degeneration. <i>Nutrients</i> , 2020, 12, 2871.	4.1	19
83	Peptidomimetics Therapeutics for Retinal Disease. <i>Biomolecules</i> , 2021, 11, 339.	4.0	10
84	Phase 2 Randomized Clinical Study of Netarsudil Ophthalmic Solution in Japanese Patients with Primary Open-Angle Glaucoma or Ocular Hypertension. <i>Advances in Therapy</i> , 2021, 38, 1757-1775.	2.9	7
85	Retrospective evaluation of two-year results with a filtering trabeculectomy in comparison to conventional trabeculectomy by exact matching. <i>F1000Research</i> , 2020, 9, 1245.	1.6	2
86	Suppression of TGF- β 2 pathway by pirfenidone decreases extracellular matrix deposition in ocular fibroblasts in vitro. <i>PLoS ONE</i> , 2017, 12, e0172592.	2.5	72
87	Rational Basis for Nutraceuticals in the Treatment of Glaucoma. <i>Current Neuropharmacology</i> , 2018, 16, 1004-1017.	2.9	20
88	Cod liver oil: a potential protective supplement for human glaucoma. <i>International Journal of Ophthalmology</i> , 2011, 4, 648-51.	1.1	16
89	Recent advances in pharmacotherapy of glaucoma. <i>Indian Journal of Pharmacology</i> , 2008, 40, 197.	0.7	51
90	Ultrasound and Microbubbles for the Treatment of Ocular Diseases: From Preclinical Research towards Clinical Application. <i>Pharmaceutics</i> , 2021, 13, 1782.	4.5	10

#	ARTICLE	IF	CITATIONS
92	Ahmed valve implantation: intraoperative and early postoperative complications. <i>Ophthalmology Journal</i> , 2014, 7, 10-12.	0.2	1
93	New Drug Targets and Drug Delivery Strategies for Various Ocular Disorders. , 2016, , 181-201.		0
94	Efficacy and Safety of Travoprost and Timolol Fixed Combination Compared to Travoprost in Patients with Primary Open Angle Glaucoma and Ocular Hypertension. <i>Open Journal of Ophthalmology</i> , 2017, 07, 176-183.	0.3	1
95	PRIMARY GLAUCOMAS- SCREENING, EVALUATION AND MANAGEMENT IN A TERTIARY CARE HOSPITAL, CENTRAL INDIA. <i>Journal of Evidence Based Medicine and Healthcare</i> , 2017, 4, 2158-2163.	0.0	0
97	Laser/Light Application in Ophthalmology: Control of Intraocular Pressure. , 2018, , 33-52.		0
98	Evaluation of Contrast sensitivity after four different treatment modalities using optec-functional vision analyzer in primary open-angle glaucoma. <i>Middle East African Journal of Ophthalmology</i> , 2019, 26, 60.	0.3	1
99	Anti-glaucoma potential of hesperidin in experimental glaucoma induced rats. <i>AMB Express</i> , 2020, 10, 94.	3.0	7
101	Retrospective evaluation of two-year results with a filtering trabeculectomy in comparison to conventional trabeculectomy by exact matching. <i>F1000Research</i> , 2020, 9, 1245.	1.6	2
102	Alloplant implant: a novel biomaterial in the management of recalcitrant glaucoma. <i>Medscape Journal of Medicine</i> , 2008, 10, 177.	0.6	0
103	Effect of CO(2) laser sclerectomy with iridectomy on ocular hypertension in rabbits. <i>International Journal of Ophthalmology</i> , 2011, 4, 30-2.	1.1	0
104	A Review on Newer Ocular Drug Delivery Systems with an Emphasis on Glaucoma. <i>Advanced Pharmaceutical Bulletin</i> , 2021, 11, 399-413.	1.4	0
105	A Review on Newer Ocular Drug Delivery Systems with an Emphasis on Glaucoma. <i>Advanced Pharmaceutical Bulletin</i> , 2020, 11, 399-413.	1.4	4
106	Imaging Methods for the Assessment of a Complex Hydrogel as an Ocular Drug Delivery System for Glaucoma Treatment: Opportunities and Challenges in Preclinical Evaluation. <i>Molecular Pharmaceutics</i> , 2022, 19, 733-748.	4.6	10
108	Subtenon triamcinolone as an adjuvant in mitomycin-C-enhanced trabeculectomy in non-inflammatory glaucomas: A randomized clinical trial. <i>PLoS ONE</i> , 2022, 17, e0268623.	2.5	0
109	Treatment Goals in Neovascular Glaucoma. <i>Essentials in Ophthalmology</i> , 2022, , 97-109.	0.1	0
110	Clinical Outcomes of the Implementation of IOP Monitoring, in and out of Office Time, to 1500 Patientsâ€™ A Cohort Study. <i>Vision (Switzerland)</i> , 2022, 6, 69.	1.2	0
111	Early Inflammation Control After Trabeculectomy by Steroid and Non-steroidal Eye Drops: A Randomized Controlled Trial. <i>Ophthalmology and Therapy</i> , 2023, 12, 969-984.	2.3	2
112	An Rna Sequencing Analysis of Glaucoma Genesis in Mice. , 2022, , .		0

#	ARTICLE	IF	CITATIONS
113	Long-Term Outcomes of Ahmed Glaucoma Valve Surgery in a Scottish Cohort of Patients With Refractory Glaucoma. <i>Cureus</i> , 2023, , .	0.5	0
114	Oral Ibuprofen is Associated With Reduced Likelihood of Early Bleb Failure After Trabeculectomy in High-Risk Glaucoma Patients. <i>Journal of Glaucoma</i> , 2023, 32, 237-244.	1.6	0
115	Investigating the Use of Pilocarpine, Timolol, and Prostaglandin Analogues in English Publications. <i>Journal of the Korean Glaucoma Society</i> , 2023, 12, 14.	0.0	0
116	Steroids and/or Non-Steroidal Anti-Inflammatory Drugs as Postoperative Treatment after Trabeculectomyâ€™ 12-Month Results of a Randomized Controlled Trial. <i>Journal of Clinical Medicine</i> , 2024, 13, 887.	2.4	0
117	A review on glaucoma: causes, symptoms, pathogenesis & treatment. <i>Journal of Clinical Research and Ophthalmology</i> , 2024, 11, 001-004.	0.1	0